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Abstract. Cancer patients commonly suffer from cachexia, a
syndrome in which tumors induce metabolic changes in the
host that lead to massive loss in skeletal muscle mass. Using
a preclinical mouse model of cancer cachexia, we tested the
hypothesis that tumor inoculation causes a reduction in ATP
synthesis and genome-wide aberrant expression in skeletal
muscle. Mice implanted with Lewis lung carcinomas were
examined by in vivo 31P nuclear magnetic resonance (NMR).
We examined ATP synthesis rate and the expression of genes
that play key-regulatory roles in skeletal muscle metabolism.
Our in vivo NMR results showed reduced ATP synthesis rate
in tumor-bearing (TB) mice relative to control (C) mice, and
were cross-validated with whole genome transcriptome data
showing atypical expression levels of skeletal muscle
regulatory genes such as peroxisomal proliferator activator
receptor Á coactivator 1 ß (PGC-1ß), a major regulator of
mitochondrial biogenesis and, mitochondrial uncoupling
protein 3 (UCP3). Aberrant pattern of gene expression was
also associated with genes involved in inflammation and
immune response, protein and lipid catabolism, mito-
chondrial biogenesis and uncoupling, and inadequate
oxidative stress defenses, and these effects led to cachexia.
Our findings suggest that reduced ATP synthesis is linked to
mitochondrial dysfunction, ultimately leading to skeletal
muscle wasting and thus advance our understanding of
skeletal muscle dysfunction suffered by cancer patients. This
study represents a new line of research that can support the
development of novel therapeutics in the molecular medicine
of skeletal muscle wasting. Such therapeutics would have
wide-spread applications not only for cancer patients, but also
for many individuals suffering from other chronic or endstage
diseases that exhibit muscle wasting, a condition for which
only marginally effective treatments are currently available.
Introduction
Cachexia is a complex metabolic syndrome that can result
from adaptation to an underlying illness; it is characterized
by loss of muscle mass with or without loss of fat mass (1).
Selective targeting of skeletal muscle is a principal feature of
cachexia pathophysiology (2), and a major cause of fatigue
(3) in patients. Indeed, the condition can rob patients of 30%
or more of their body weight (4). As many as half of untreated
cancer patients present with cachexia (5,6), which is most
commonly associated with cancers of the gastrointestinal
tract and lung (6); furthermore, in these cancer types muscle
wasting occurs at a faster rate than any other known situation
in human subjects (6-8).
Cancer-induced muscle wasting is typically associated
with the development of significantly increased resting energy
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expenditure (REE) in skeletal muscle and fat (6,7,9)-REE
increases as a result of decreased caloric intake and/or increased
energy expenditure. Uncoupling proteins (UCPs) have been
implicated in the control of energy metabolism (6,7). They
transport protons into the mitochondrial matrix (10) and non-
esterified fatty acid (FA) anions out of the matrix in a process
called FA cycling (11). Both of these processes reduce the
proton gradient across the inner mitochondrial membrane,
thereby dissipating energy as heat (7) and thus increasing
energy expenditure. Strong evidence indicates that cancer-
induced cachexia induces UCP2 and UCP3 at the transcrip-
tional and translational levels in skeletal muscle via tumor
necrosis factor alpha (TNF·) (12-14). This induction correlates
directly with antioxidative activity as production of reactive
oxygen species (ROS) increases as a result of mitochondrial
dysfunction (15,16). Inflammatory cytokines are considered
to be mediators of and targets for cancer cachexia (17-20);
they have been reported to lead to post-transcriptional activa-
tion of the peroxisomal proliferator activator receptor Á
coactivator 1 · (PGC-1·) via the p38 mitogen-activated protein
kinase (MAPK) pathway, resulting in increased respiration
in muscle cells (21). In addition, it has been shown that
decreased PGC-1· expression leads to profoundly reduced
mitochondrial content and activity (22), while increased
PGC-1· protein levels have been observed in a rat cancer
cachexia model (23). It is now well established that mito-
chondrial function can be altered via coordinated changes in
gene expression (24).
In vivo NMR spectroscopy enables quantification of
intracellular physiological variables in an organism without
removal or destruction of the tissue to be examined, as other
techniques usually require to make such an assessment (25,26).
Indeed, in vivo NMR represents a significant advance in the
study of mitochondrial function by providing measurements
under physiological conditions in intact skeletal muscle,
thus eliminating in vitro artifacts. With this methodology,
researchers can measure the net skeletal muscle rate of
oxidative ATP synthesis catalyzed by mitochondrial ATPase
(27,28), which by definition is proportional to oxygen
consumption by the P/O ratio (the ratio of the net rate of
ATP synthesis by oxidative phosphorylation to the rate of
oxygen consumption) (29,30). Furthermore, in vivo NMR in
combination with whole-genome analysis of gene expression,
which provides a snapshot of the transcriptome in a specific
tissue in response to experimentally defined physiological
conditions, provides a systematic approach for studying
complex systems, such as cancer-induced muscle wasting, by
integrating mitochondrial function data with information
about mitochondrial regulation at the cellular and organism
levels.
Although mitochondrial dysfunction, has been shown in
experimental models of burn injury to lead to skeletal muscle
wasting (31-39), it has never been studied in the context of
cancer-induced cachexia. The aim of the present study was to
study mitochondrial function in cancer cachexia holistically
in a suitable preclinical model. To this end, highly cachectic,
fast-growing Lewis lung carcinomas, characterized by poorly
differentiated cells with a short doubling time (40), were
implanted in mice. This model is advantageous owing to the
fast rate of muscle wasting produced and lack of anorexia
which produce a clear cachectic state characterized by
profound muscle wasting (40-44), mimicking closely the
pathophysiology of untreated human cancer cachexia. We
hypothesize that mitochondrial dysfunction triggered by an
altered gene expression program is a major cause of skeletal
muscle wasting in cancer. To test this hypothesis, in vivo
NMR combined with whole-genome expression analysis was
applied to intact Lewis lung carcinoma-inoculated mice and
the data were compared to data from control (C) tumor-free
mice to assess alterations in the tumor bearing (TB) animals'
bioenergetic status and to characterize concomitant gene
expression patterns in cancer-induced cachectic versus control
skeletal muscle tissue.
Materials and methods
Animals. C57Bl/6 mice (20-25 g) (Charles River Laboratories,
Boston, USA) were used as a representative inbred stock and
reliable population for the microarray studies. The animals
were maintained at 22±2˚C with a regular light-dark cycle
(lights on from 8:00 am to 8:00 pm) and had free access to
standard rodent chow and water. The diet consisted of 54%
carbohydrate, 17% protein, and 5% fat (the residue was non-
digestible material). Food intake was measured daily; food
provided daily was pre-weighted. After 24 h, remaining food
was weighted and subtracted from the initially provided food.
The net value of food consumed every 24 h gave the rate of
food intake. Only male mice were used in order to avoid the
variability that can result from the female estrous cycle. All
animal experiments were approved by the Subcommittee on
Research Animal Care of Massachusetts General Hospital,
Boston.
Tumor implantation. Mice were inoculated with tumor
according to an established protocol (43) under short-time
isoflurane anesthesia (3% in O2) as described previously (43).
Animals were randomized into tumor-free control (C) and
tumor-bearing (TB). TB-mice received an intramuscular
(right hind leg) inoculum of 4x105 Lewis lung carcinoma
cells obtained from exponential tumors.
Evaluation of cancer induced cachexia. Fourteen days after
tumor transplantation, the mice were weighed and anes-
thetized with an intraperitoneal (i.p.) ketamine (87 mg/kg)
and xylazine (13 mg/kg) injection. Tumor, tissues of interest
and blood were collected. All mice were then administered a
lethal dose of pentobarbital (200 mg/kg, i.p.). The cancer-
induced cachexia was evaluated by measuring: i) the total
body and carcass (muscle + bone + skin) weights, ii) the
weight of gastrocnemius, tibialis, soleus and extensor
digitorum longus (EDL) muscle weights in the contralateral
(left leg) to the tumor bearing leg as described previously
(43), and iii) the TNF·, interleukin-6 (IL-6) and interleukin-
10 (IL-10) levels in blood using Q-Plex™ Mouse Cytokine/
Chemokine kit by Quansys Biosciences laboratory (USA).
(www.quansysbio.com/products-services/sample-testing).
31P NMR spectroscopy
Data acquisition. The theoretical basis of saturation transfer
experiments has been described previously by Forsen and
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Hoffman (45). Animals were subjected to in vivo 31P NMR
spectroscopy 14 days after tumor inoculation. The mice were
transiently anesthetized with a mixture of isoflurane (3.0%)
and O2 (2.0 l/min) delivered through a nose cone and placed
in a customized restraining tube. Each animal's left hind limb
was placed into a solenoid coil (four turns; length, 2 cm;
diameter, 1 cm) tuned to 31P frequency (162.1 MHz). During
the MR imaging, mice were kept anesthetized with a mixture
of isoflurane (1.5%) and O2 (0.6 l/min). The rectal body
temperature was maintained at 37±1˚C using heated water
blankets. All in vivo 31P NMR experiments were performed
in a horizontal bore magnet (proton frequency at 400 MHz,
21 cm diameter, Magnex Scientific, Varian, Palo Alto, CA,
USA) using a Bruker Advance console. Field homogeneity
was adjusted using the 1H signal of tissue water. A 90˚ pulse
was optimized for detection of phosphorus spectra (repetition
time 2 sec, 400 averages, 4,000 data points). Saturation 90˚
selective pulse trains (duration, 36.534 ms; bandwidth, 75 Hz)
followed by crushing gradients were used to saturate the
ÁATP peak. The same saturation pulse train was also applied
downfield of the inorganic phosphate (Pi) resonance, symme-
trically to the ÁATP resonance. T1 relaxation times of Pi and
phosphocreatine (PCr) were measured using an inversion
recovery pulse sequence in the presence of ÁATP saturation.
An adiabatic pulse (400 scans; sweep width, 10 kHz; 4,000
data points) was used to invert Pi and PCr, with an inversion
time between 152 and 7,651 ms.
Data analysis. 31P NMR spectra were analyzed using the
MestRe-C NMR software package (Mestrelab Research,
NMR solutions, website: www.mestrec.com). Free induction
decays were zero-filled to 8,000 points and apodized with
exponential multiplication (30 Hz) before Fourier trans-
formation. The spectra were then manually phased and cor-
rected for baseline broad features. The Levenberg-Marquardt
algorithm was used to least-square-fit a model of mixed
Gaussian/Lorentzian functions to the data. Similarly, the T1obs
relaxation time for Pi and PCr was calculated by fitting the
function y = A1[1-A2e-(t/T1obs)] to the inversion recovery data,
where y is the z magnetization and t is the inversion time.
Total RNA extraction. The mice were anesthetized by intra-
peritoneal injection of ketamine (87 mg/kg) and xylazine
(13 mg/kg) and the gastrocnemius muscle contralateral (left)
to the TB-hind leg was rapidly excised, weighed, and frozen
in liquid nitrogen. Left gastrocnemius muscles excised from C
animals served as controls specimens. All mice were then
administered a lethal dose of pentobarbital (200 mg/kg, i.p.).
Frozen biopsies from TB and C mice (n=4) were immersed
in 1 ml TRIzol® (Gibco-BRL, Invitrogen, Carlsbad, CA) for
RNA extraction. Each muscle specimen was homogenized for
60 sec with a Brinkman Polytron 3000 homogenizer before
extraction of total RNA. Chloroform (200 μl) was added to
each homogenized muscle specimen and mixed by inverting
the tube repeatedly for 15 sec. After centrifugation at 12,000 x g
for 15 min, the upper aqueous phase was transferred by pipet
to a new tube and precipitated by adding 500 μl of isopropanol.
Further centrifugation at 12,000 x g for 10 min condensed
the RNA pellet, which was then washed with 500 μl of 70%
ethanol and centrifuged at 7,500 x g for 5 min prior to air
drying. The pellet was resuspended in 100 μl DEPC-H20. An
RNeasy kit (Qiagen, Germantown, MD) was used to purify
the RNA according to the manufacturer's protocol. Purified
RNA was quantified by UV absorbance at 260 and 280 nm
and stored at -70˚C for DNA microarray analysis.
Gene array hybridization and analysis. Biotinylated cRNA
was generated from 10 μg aliquots of total RNA, and hybri-
dized onto MOE430A oligonucleotide arrays, which were
subsequently stained, washed, and scanned. All procedures
followed standard Affymetrix protocols (Santa Clara, CA).
The hybridized array image data files were converted to cell
intensity (CEL) files in Microarray Suite 5.0 (MAS 5.0,
Affymetrix). The data were scaled to a target intensity of 500,
and Genespring GX (version 7.3) software (Agilent Techno-
logies) was employed for statistical analysis of differential
transcript expression using the Welch t-test for multiple testing
correction and Benjamini and Hochberg False Discovery Rate
(cut-off of 5% false discovery rate and 2-fold change). Probe
sets representing the same transcript were ordered on their
corresponding unigenes, and the 3'-most probe set was selected
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Table I. Cancer cachexia effects in C57BL/6 mice.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Control Tumor-bearing (day 14) P-value
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Initial BW (g) 17±0.2 (n=5) 17±0.5 (n=8) NS
Final BW (g) 22±1 (n=5) 14±1 (n=8) <0.001
% weight change 29% -17%
Carcass (mg/100 g initial BW) 77±2 (n=5) 56±1 (n=8) <0.001
Muscles weights (mg/100 g initial BW)
Gastrocnemius 764±16 (n=6) 381±6 (n=8), -50.2% <0.001
Tibialis 241±8 (n=6) 123±7 (n=8), -49% <0.001
Soleus 42±1 (n=6) 37±3 (n=8), -11.9% NS
EDL 58±4 (n=6) 39±3 (n=8), -32.8% <0.01
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Results are expressed as mean ± SEM for the number of animals indicated in parentheses. EDL, extensor digitorum longus; NS, not
significant; carcass weight, muscle + bone + skin.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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from combined lists of all probe sets. A collection of genes
with experimental evidence was compiled using MOE430A
chip annotation (Affymetrix, retrieved December, 2009)
compiled from GeneSpring GX (version 7.3). Statistically
significant sets of functionally related genes were selected
using overrepresentation statistics calculated as hypergeo-
metric probabilities using all genes selected in each experiment
that had Gene Ontology annotation for biological process
(46) using Gene Ontology Analysis (GeneSpring GX, version
7.3). Functions' P-values were estimated using 0.05 as the
cut-off point (GeneSpring GX, version 7.3). Functional
categories that did not have at least two genes were removed. 
Results
Lewis lung carcinoma inoculation decreased body, carcass
and skeletal muscle weights. Food intake during the experi-
ment did not differ between TB and C groups. Fourteen days
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Figure 1. NMR spectra of in vivo 31P NMR saturation-transfer performed on the hind limb skeletal muscle of awake mice. Representative summed 31P-NMR
spectra acquired from C and TB mice before (A) and after (B) saturation of the Á-ATP resonance. The arrow on Á-ATP indicates the position of saturation
(sat) by rf irradiation (-2.4 ppm). ppm, chemical shift in parts per million.
Table II. Results of in vivo 31P-NMR saturation transfer experiments performed on the hindlimb skeletal muscle of mice.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Control Tumor-bearing Δ(%) P-value
(n=10) (n=6)
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
ATP synthesis flux (reaction Pi➝ÁATP)
ΔM/M0 0.484±0.036 0.304±0.051 -37.2 0.011
T1obs (s) 1.59±0.14 1.50±0.14 -5.6 NS
κf  (s-1) 0.304±0.026 0.203±0.038 -33.2 0.038
ATP (mmol/g) 1.19±0.14 0.87±0.19 -26.9 0.054
Pi (mmol/g) 0.280±0.062 0.222±0.079 -20.7 NS
ATP synthesis rate (mmol/g/s) 0.085±0.013 0.045±0.013 -47.1 0.029
ATP synthesis flux (reaction PCr➝ATP)
ΔM/M0 0.24±0.02 0.26±0.02 +8.3 (NS)
T1obs (s) 1.59±0.20 1.50±0.27 -5.7 (NS)
κf  (s-1) 0.15±0.02 0.17±0.03 +13.3 (NS)
ATP (μmol/g) 1.19±0.28 0.87±0.19 -26.9 (NS)
PCr (μmol/g) 4.13±0.99 2.65±0.59 -35.8 0.015
ATP synthesis rate (μmol/g/s) 0.62±0.17 0.45±0.13 -27.4 0.036
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Values are means ± SEM; ΔM/M0 is the fractional change in Pi or PCr magnetization as a result of saturation transfer; T1obs is the observed
spin lattice relaxation time of Pi or PCr during ÁATP saturation in seconds; κf is the rate constant for the reactions Pi ➝ ATP and PCr ➝ ATP,
calculated as (1/T1obs) x (ΔM/M0). ATP synthesis is calculated as [Pi] or [PCr] x κf. A bioluminescence assay kit was used to assess ATP
concentration. Δ (%), percent change. NS, not significant. Unpaired Student's t-test was used for the comparisons.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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after tumor implantation mean total body weight (BW) of TB
mice had decreased by 17% relative to pre-inoculation
(Table I). BW loss was associated with a 27.3% decrease in
carcass weight (muscle + bone + skin) (Table I). Muscle mass
was decreased 14 days after tumor implantation in all tissues
studied, with the most substantial decreases being observed in
the gastrognemnius (50.2% decrease), tibialis (49.0%
decrease), and EDL (32.8% decrease) muscles (Table I).
Lewis lung carcinoma inoculation increased blood levels of
cytokines. TB mice had elevated levels of the procachectic
cytokines TNF· (77.2% greater than C; P=0.02) and IL-6
(8,120.1% greater than C; P=0.01) 14 days after tumor
implantation. Moreover, IL-10, which was undetectable in C
mice, was also present at high levels (26.12±4.06 pg/ml) in TB
mice.
Cancer cachexia reduced ATP synthesis rate. 31P NMR spectra
acquired from TB and C mice, before and after saturation of
the ÁATP resonance, with the mean results and their percent
change (Δ) presented in Table II. The unidirectional synthesis
rate of the Pi ➝ Á-ATP reaction in TB mice was 47% lower
than that observed in C mice (P=0.029). This synthesis rate
involves measurements from NMR and from a biochemical
assay (ATP concentration measurement), and both were
significantly decreased in the cancer mice. The NMR-measured
fractional change ΔM/M0 was decreased by 37% in TB mice
relative to the C group (percent change in ΔM/M0, Table I).
ATP concentration (14 days post-inoculation) was lower in TB
than in C mice by approximately 27% (Table II), a difference
that approached significance (P=0.054) in the unidirectional
(one-tailed) t-test. ATP synthesis rate was significantly reduced
in TB mice (47% lower than in C) in the unidirectional (one-
tailed) t-test (P=0.029). The fractional change, ΔM/M0, and
the observed spin lattice relaxation time, T1obs, were used to
calculate the  κf rate constant using the equation (1/T1obs) x
(ΔM/M0). The ATP synthesis flux was then obtained as the
product of κf and Pi concentration. Accordingly, the uni-
directional synthesis rate of the PCr ➝ Á-ATP reaction was
also 27% lower in TB mice compared to C, a difference that
was significant according to a unidirectional (one-tailed)
t-test (P=0.036).
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Figure 2. Distribution of genes differentially expressed in gastrocnemius muscle of TB animals relative to C animals among 14 functional categories showed
in the X axis, as identified by using Gene Ontology and KEGG metabolic pathways at P≤0.05. Gray bars indicate the number of upregulated genes while
black bars correspond to down-regulated genes in the gastrocnemious muscle of TB animals versus C animals (left Y axis). The negative log10 of P-values
represented by diamonds are indicated in the right Y axis. 
Figure 3. Summary of the magnitudes of change in mRNA expression of
mitochondrial function-related and other cancer-induced cachexia-related
genes 14 days after cancer transplantation. IRS-1, insulin receptor substrate
1; IGF-1, insulin-like growth factor 1; IGFBP-5, insulin-like growth factor
binding protein 5; PDK4, pyruvate dehydrogenase kinase 4; PGC-1ß,
peroxisome proliferator-activated receptor-Á coactivator-1ß; UCP3,
uncoupling protein 3; FoxO3·, Forkhead box O3·; ATROGIN-1, F-box
only protein 32; UBE3a, ubiquitin protein ligase E3A; SOD-2, superoxide
dismutase 2; GPX, glutathione peroxidase 3.
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Cancer-induced cachexia affected several cellular functions
in skeletal muscle. Analysis of transcriptome studies
identified 611 genes as differentially expressed in skeletal
gastrocnemius muscle in TB versus C mice (P<0.05).
Comparison of these 611 differentially expressed genes to
annotations in the Gene Ontology Consortium enabled
functionally related sets of genes to be identified and
subsequent analysis of these data indicated that several
cellular functions were altered by cancer-induced cachexia
(Fig. 2). The four most prominently affected functions were
related to inflammation and immune response, and these
effects predominantly involved significant increases in
transcription. The four next most prominently affected
functional categories involved genes whose products mediate
protein metabolism, especially protein degradation.
Specifically, as shown in Fig. 2, transcription of molecules
involved in protein catabolism, protein depolymerization, and
proteasome-related was altered, mostly in the direction of
upregulation. The ubiquitin-proteasome pathway in particular
was implicated as a major process of protein degradation in
cancer-induced cachexia. Transcription of protein maturation
related genes was universally down-regulated in TB mice.
The transcriptome analysis revealed cancer-induced alter-
ations in cellular lipid metabolism and lipid catabolism in TB
mice relative to C mice (Fig. 2), indicating that cancer-induced
cachexia also begets abnormal lipid metabolism. Among the
down-regulated genes (data not shown) was stearoyl-
Coenzyme A desaturase 1, which encodes for the first (step-
limited) enzyme in unsaturated fatty acid biosynthesis.
Phospholipase A2 and phospholipase C, which have roles in
several lipid metabolic and signaling pathways, were also
differentially affected. Genes related to skeletal muscle anti-
oxidative capacity were affected by cancer cachexia as well
(last two functional catagories listed in Fig. 2). While increased
transcription of genes related to oxidative stress response was
evident, superoxide metabolism genes were down-regulated.
Differential expression of key mitochondrial genes in cancer
cachexia. Fig. 3 shows the effect of cancer-induced cachexia
on the expression levels of selective genes related to mito-
chondrial function. Specifically, uncoupling protein 3 (UCP3),
and forkhead box O 3· (FoXO3·) expression levels were
significantly upregulated (P=0.03 and P=0.04 respectively). As
well as pyruvate dehydrogenase kinase 4 (PDK4), an inhibitor
of pyruvate dehydrogenase complex (P=0.01). Meanwhile,
peroxisome proliferator activated receptor-Á coactivator-1ß
(PGC-1ß) was significantly down-regulated (P=0.04).
It is noteworthy that the present experiments revealed
also altered expression of genes known to be involved in the
IGF-1/AKT pathway which regulates: a) signaling pathways
responsible for FoXOs post-translational activation; and b)
protein synthesis and degradation (Fig. 3). More specifically,
our data suggest that cachexic animals had decreased AKT
activation since insulin-like growth factor 1 (IGF-1), insulin
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Figure 4. Putative PGC-1-mediated mechanism of cancer-induced skeletal muscle wasting. In this model, significant down-regulation of PGC-1ß expression
causes dysregulation of mitochondria, resulting in reduced ATP synthesis and increased ROS production, most likely due to PGC-1-dependent upregulation of
UCPs. Meanwhile, reduced PGC-1ß gene expression levels result in a failure to down-regulate expression of FoXO3·, which normally suppresses atrogen
expression and proteolysis. Insulin-stimulated IGF-1/AKT pathway signaling is also significantly attenuated. Thus, AKT does not phosphorylate FoXOs and,
consequently, favors further upregulation of atrogenes, thus leading to skeletal muscle wasting. Moreover, reduced IGF-1/AKT signaling further facilitates
protein translation inhibition due to mTOR inactivation which also results in cachexia. Meanwhile, PGC-1ß may affect IGF-1 and IRS-1 expression thereby
producing insulin resistance in skeletal muscle. IRS-1, insulin receptor substrate 1; IGF-1, insulin-like growth factor 1; PGC-1s, peroxisome proliferator-
activated receptor-Á coactivators-1; UCPs, uncoupling proteins; FoXOs, forkhead box O proteins; ROS, reactive oxygen species; TNF·, tumor necrosis factor ·;
NF-κB, nuclear factor-κB.
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receptor substrate 1 (IRS-1), and IGF binding protein 5
(IGFBP5) were all significantly down- regulated in TB mice
(P=0.03, P=0.02 and P=0.048 versus C, respectively).
Furthermore, the ubiquitin-proteasome pathway related genes
atrogin-1 and ubiquitin-conjugating enzyme E3 (UBE3·) were
upregulated in skeletal muscle of TB mice (P=0.0495 and
P=0.0252 versus C, respectively); and the eukaryotic translation
initiation factor 4E binding protein 1 (EIF4Ebp1) was also
significantly up-regulated in TB mice (P=0.0077 versus C).
Genes related to antioxidative capacity were also differentially
expressed in TB mice: superoxide dismutase 2 (SOD2) was
down-regulated (P=0.0111 versus C) while glutathione
peroxidase 3 (GPX) was upregulated (P=0.0068 versus C).
Discussion
In this study, we used a combined approach of in vivo NMR
together with whole-genome expression analysis to investi-
gate mitochondrial function and elucidate a possible regulatory
molecular mechanism that may mediate skeletal muscle
wasting in an experimental preclinical murine model of cancer
cachexia. Our animal model was validated by our findings of
weight decreases in total body, carcass and several skeletal
muscles 14 days after tumor implantation, observations that
corroborated prior findings (43). Further validation of our
model was provided by our genomic data which showed
aberrant gene expression in several cellular functions related
to cancer cachexia; the affected genes were most prominently
found to be involved in immune-inflammatory response,
protein degradation, lipid metabolism and antioxidative defense
mechanisms. Increased immune-inflammatory response is
consistent with the pathophysiology of cancer-induced
cachexia described in previous reports (47,48), while protein
degradation is considered to be a major cause of cachexia (2).
Furthermore, the cancer-induced alterations in cellular lipid
metabolism reported in this study are also indicative of
abnormal lipid metabolism in cachexia, in agreement with
previous observations (49).
The present in vivo NMR spectroscopy studies, which
allowed measurements of physiological biomarkers (25,26),
showed a significantly reduced ATP synthesis rate in cachexic
mice suggestive of bioenergetic mitochondrial dysfunction.
Our accompanying whole-genome expression experiments
complemented our NMR findings, revealing aberrant expres-
sion of genes involved in mitochondrial biogenesis (PGC-1ß),
and uncoupling (UCP3) in a clinically relevant cancer
cachexia model. Interestingly, our NMR findings of mito-
chondrial dysfunction in the skeletal muscle of animals
exhibiting cancer cachexia are similar to prior observations
in murine models of burn trauma (31,37). In vivo 31P-NMR
saturation-transfer can non-invasively measure fast enzyme
reaction exchange rates (50) and, in particular, the net rate of
oxidative ATP synthesis catalyzed by mitochondrial ATPase
in skeletal muscle, which is proportional to the oxygen
consumption rate according to the P:O ratio (the ratio of the
net rate of ATP synthesis by oxidative phosphorylation to the
rate of oxygen consumption) (29,30). It has been proposed
that NMR-measured unidirectional ATP synthesis flux
primarily reflects flux through F1F0-ATP synthase, with
negligible influence of the coupled glyceraldehyde-3-phos-
phate dehydrogenase and phosphoglycerate kinase reactions
for ATP production (28,51). Because these enzymes occur at
near equilibrium, unidirectional production of ATP can be
high. Furthermore, since cancer cachexia upregulates
expression of PDK4 (in mouse Fig. 3; in rat, see (23), a well
established inhibitor of the pyruvate dehydrogenase complex
which is involved in controlling the use of glucose-linked
substrates as sources of oxidative energy via glycolysis (52),
we can assume that the contribution of glycolytic reactions to
unidirectional ATP synthesis flux is negligible.
In agreement with our NMR findings, our genomic
experiments revealed reduced expression of PGC-1ß, a mito-
chondrial biogenesis transcription factor. Reduced expression
of PGC-1ß has also been observed in murine burn-induced
skeletal muscle wasting models (31,37), while increased
PGC-1· protein levels have been previously reported in a rat
cancer cachexia model (23), strongly supporting the view that
PGC-1s play a key role in cancer-induced muscle wasting.
Specifically, it has been suggested that PGC-1· protects
skeletal muscle from atrophy (53) while PGC-1ß expression
has been associated with an increase in ATP-consuming
reactions (24). Moreover, reduced PGC-1 expression levels
have also been correlated to profoundly reduced mito-
chondrial content and activity (22); these effects may be due
to the action of UCPs (34) given that down-regulation of
PGC-1s is accompanied by increased UCP expression in
murine models of both cancer- (12,14,23) and burn-related
cachexia (31,54). Increased levels of UCPs dissipate the
proton gradient and lower the mitochondrial membrane
potential, a process known to increase energy expenditure by
dissipating energy as heat (7). The presently observed
upregulation of UCP3 in cachexic animals corroborates
previous findings (12-14,16).
Indeed, this increase in UCP3 gene expression suggests
that there was mitochondrial uncoupling in TB mice since
increased levels of UCPs lower the mitochondrial membrane
potential (55) and thus greatly reduce the amount of ROS in
mitochondria (56,57), a major site of ROS production in the
cell (58,59), especially in conditions characterized by high
TNF· levels (60), such as cancer. To this end, it has been
proposed that upregulation of UCPs in cancer may be directly
related to the antioxidative capacity of skeletal muscle, thus
involving UCPs in a counter-regulatory mechanism to lower
ROS production; this process is thought to involve the
muscle anabolic cytokine IL-15 (16). UCP expression has
been reported to be upregulated by procachectic cytokines
(TNF· and IL-6) via p38MAPK-dependent post-translational
activation of PGC-1s (21). Our data agree with this notion, as
we observed increased levels of the procachectic cytokines
TNF· and IL-6 in TB mice relative to C mice (by 77.2% and
8,120.1%, respectively). 
A principal finding of the present study was that down-
regulation of PGC-1ß in TB mice was accompanied by a
down-regulation of SOD2 as well as an upregulation of GPX.
Interestingly, it has previously been shown that PGC-1s
increase gene expression of SOD2, GPX and enzymes respon-
sible for glutathione biosynthesis (24), and both SOD2 and
GPX have been implicated in cancer-induced oxidative stress
response (61-63). Our results indicate that muscle defense
against oxidative stress in cancer is mediated largely by
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GPX, corroborating the observed increase in genes ascribed
to the ‘response to oxidative stress’ function. Meanwhile, genes
ascribed superoxide metabolism function were expressed at
significantly lower levels in TB mice than in C mice, indicating
that the defense mechanisms functioning in cancer cachexia
are not adequate to handle the oxidative stress with which
they are faced.
Another principal finding of our study is that decreased
expression of PGC-1ß was accompanied by increased FoXO3·
gene expression levels. This finding is consistent with a
previous report suggesting that PGC-1s inhibit FoXOs-
dependent transcription (53) and provides support for the view
that PGC-1ß may play a central regulatory role in cancer-
induced cachexia given that FoXOs are involved in multiple
signaling pathways and play critical roles in numerous
physiological and pathological processes including cancer
(64). Specifically, FoXOs are under regulatory influences at
multiple levels, including phosphorylation, acetylation/
deacetylation, ubiquitination, and protein-protein interactions
(64). Furthermore, in the present study, we also report
aberrant expression of genes known to be involved in the
IGF-1/AKT pathway, which has been reported to play a role
in FoxOs post-translational activation (65,66). Involvement
of the IGF-1/AKT pathway in cancer cachexia (67) was
confirmed by our data showing decreased AKT activation as
evidenced by down-regulated IGF-1, IRS-1 and IGFBP5.
Consequently, decreased AKT activation could permit
dephosphorylation of FoXOs and thus translocation of FoXOs
to the nucleus, where they are activated and promote upregu-
lation of genes related to protein degradation (53,66,68,69),
namely atrogin-1 and ubiquitin-conjugating enzyme E3, thus
leading to cachexia. Genes related to the structure of the
proteolytic system (proteasome function in Fig. 2) were also
upregulated in TB mice, further implicating activation of the
ubiquitin-proteasome pathway as a major generator of protein
degradation in cancer-induced cachexia, as previously reported
in cancer patients exhibiting weight loss (70).
The hypothesis that IGF-1/AKT attenuation contributes to
cancer cachexia is supported by the presently observed
elevated levels of the EIF4Ebp1 in TB mice, as EIF4Ebp1
levels have been found to correlate with cancer development
and cachexia (71,72) due to inhibition of protein synthesis
(73) via binding to eukaryotic initiation factor 4E (eIF4E)
(74). Specifically, hypophosphorylated EIF4Ebp1 binds to
eIF4E and prevents recruitment of the 40S ribosomal subunit
to mRNA, thus inhibiting cap-dependent translation. Binding
of EIF4Ebp1 to eIF4E is regulated by mTOR-mediated phos-
phorylation (73). Upon its activation, mTOR phosphorylates
EIF4Ebp1; hyperphosphorylated EIF4Ebp1 is released from
eIF4E, leading to an increase in cap-dependent translation
(75). Given that mTOR activation is regulated mainly by the
IGF-1/AKT pathway, attenuation of AKT activity as observed
in our experimental cancer cachexia model should further
facilitate protein translation inhibition due to mTOR inactiva-
tion and the consequent hypophosphorylation of EIF4Ebp1.
In light of the afore-mentioned lines of evidence and
previous reports, we propose here that PGC-1 acts as a key
regulator of cancer-induced bioenergetic dysfunction and
muscle wasting in experimental cancer cachexia, as illustrated
in Fig. 4. Specifically, we propose that cancer induction of
cachexia involves: i) decreased expression of PGC-1ß, which
normally inhibits FoXOs; and ii) attenuated AKT activity,
which both enable activation of FoXO3· and upregulate the
expression of atrogenes, which then facilitate muscle degra-
dation. In addition, attenuation of AKT can inhibit protein
synthesis since the IGF-1/AKT pathway normally contributes
to protein synthesis via mTOR. Meanwhile, decreased
expression of PGC-1ß appears to: a) upregulate UCP3, leading
to uncoupling and reduced ATP synthesis rate; and b) alter
immuno-inflammatory gene expression in skeletal muscle [in
cachexia Fig. 1; in experimental burn injury (31,33,34,36)].
This supposition is in agreement with other studies suggesting
that upregulation of mRNA and protein expression of UCP2
and UCP3 (12-14) correlates directly with antioxidative
capacity (15,16) in response to elevated TNF·-induced ROS
production in cancer (60).
In conclusion, because hallmarks of skeletal muscle
wasting can be detected by in vivo NMR, our findings are
clinically relevant in as much as they can be used as molecular
medicine biomarkers that can be translated to humans.
Moreover, if PGC-1s mediate key regulatory functions in
cancer-induced cachexia as suggested by the present findings,
they could serve as funnels where several oncogenic/ cachectic
signals (cytokines, ROS, IGF-1) converge to drive the down-
stream physiological response (mitochondrial dysfunction,
antioxidative and immune-inflammatory response, protein
synthesis and degradation) of skeletal muscle to malignancy.
Because PGC-1ß is a highly inducible factor in most tissues
that responds to common calcium and cAMP signaling
pathways, it is conceivable that drugs could be developed with
the ability to induce PGC-1ß and thereby directly alleviate
mitochondrial dysfunction. Such a novel therapeutic approach
could revolutionize cancer cachexia treatment.
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